We were unable to identify mutations in EMSY, BRIP, BARD1, and FOXM1 CNV in high-grade ovarian carcinoma as well as PTEN loss in clear cell carcinoma, LRPB1 loss and SOX17 amplification in uterine serous carcinoma (Table 2). Here, SOX17 is linked to endometrial serous adenocarcinoma.